# Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer

> **NCT03822845** · PHASE2,PHASE3 · COMPLETED · sponsor: **Michael Graham PhD, MD** · enrollment: 6 (actual)

## Conditions studied

- Prostatic Neoplasms
- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **DRUG:** Ga-68 PSMA-HBED-CC PET

## Key facts

- **NCT ID:** NCT03822845
- **Lead sponsor:** Michael Graham PhD, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-01
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-03-30
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822845, "Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03822845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*